Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / RNF113A



This biomarker is also known as:
  • RING finger protein 113A,
  • ZNF183,
  • RNF113,
  • zinc finger protein 183 (RING finger, C3HC4 type),
  • Cwc24,
  • Zinc finger protein 183,
  • ring finger protein 113A,

View in BioMuta


RNF113A is a member of the RNF family, or RING-type zinc finger proteins. The RNF proteins are a subset of the larger family of zinc finger proteins. Members of the RNF family have an enzyme activity known as E3 ubiquitin-protein ligase which targets other proteins to be degraded within cells. RNF113A contains a C3H1-type zinc finger domain and a C3HC4 Ring-type (Really Interesting New Gene-type) zinc finger domain. The Ring-type zinc finger domain is present in various tumor suppressors, DNA repair genes and cytokine receptor-associated molecules, and is implicated in mediating protein-protein interactions.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: RNF113A


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


RNF113A is a RING-type zinc finger protein. Several RING-type zinc finger proteins act as tumor suppressors. BRCA1 is also a RING-type zinc finger protein, with the same C3HC4 Ring-type zinc finger domain as RNF113A. Mutations in the tumor suppressor BRCA1 are widely known to contribute to the development of breast cancer.

Performance Comment

RNF113A was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.